ALK and cancer: Focusing on sex‐related type of cancer, we observed that 7/392 (1.8%) males, suffered of prostate cancer [median age: 63 years (range: 55–81); 6 treated with HU and 1 with ALK] and that 13/634 females (2.1%) suffered of breast cancer [median age: 63 years (range: 38–78), eight treated with HU, two with HU and ALK, and three not treated at all].